S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
Log in

Alkermes Stock Price, Forecast & Analysis (NASDAQ:ALKS)

$20.08
-0.04 (-0.20 %)
(As of 11/21/2019 04:00 PM ET)
Today's Range
$19.85
Now: $20.08
$20.37
50-Day Range
$17.14
MA: $19.23
$21.00
52-Week Range
$17.11
Now: $20.08
$37.75
Volume1.72 million shs
Average Volume1.22 million shs
Market Capitalization$3.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.77
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALKS
CUSIPG0176710
Phone353-1772-8000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.09 billion
Cash Flow$0.59 per share
Book Value$7.54 per share

Profitability

Net Income$-139,310,000.00

Miscellaneous

Employees2,300
Market Cap$3.16 billion
Next Earnings Date2/13/2020 (Estimated)
OptionableOptionable

Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.


Alkermes (NASDAQ:ALKS) Frequently Asked Questions

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

How were Alkermes' earnings last quarter?

Alkermes Plc (NASDAQ:ALKS) issued its quarterly earnings results on Wednesday, October, 23rd. The company reported ($0.04) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.21) by $0.17. The firm earned $255.24 million during the quarter, compared to analysts' expectations of $252.65 million. Alkermes had a negative net margin of 18.71% and a negative return on equity of 6.08%. Alkermes's quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.07 EPS. View Alkermes' Earnings History.

When is Alkermes' next earnings date?

Alkermes is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Alkermes.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes updated its FY19 earnings guidance on Wednesday, October, 23rd. The company provided earnings per share (EPS) guidance of $0.44-0.57 for the period, compared to the Thomson Reuters consensus estimate of $0.37. The company issued revenue guidance of $1.14-1.19, compared to the consensus revenue estimate of $1.18 billion.

What price target have analysts set for ALKS?

10 equities research analysts have issued twelve-month price targets for Alkermes' stock. Their forecasts range from $20.00 to $34.00. On average, they anticipate Alkermes' share price to reach $26.44 in the next year. This suggests a possible upside of 31.7% from the stock's current price. View Analyst Price Targets for Alkermes.

What is the consensus analysts' recommendation for Alkermes?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 2 sell ratings, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alkermes.

What are Wall Street analysts saying about Alkermes stock?

Here are some recent quotes from research analysts about Alkermes stock:
  • 1. According to Zacks Investment Research, "Alkermes posted narrower-than-expected loss and sales beat estimates in the first quarter of 2019. With the increasing traction of Aristada in the market, the company continues to emerge as a leader in the treatment of schizophrenia. This year will be an important one for the company’s late-stage pipeline, highlighted by the planned submission of the NDA for ALKS 3831 and the regulatory review of the recently submitted NDA for diroximel fumarate for multiple sclerosis, with action expected in the fourth quarter. The company also expects to release data from ALKS 4230's anti-tumor response study in 2019. However, Alkermes is highly dependent on manufacturing and/or royalty revenues from partners, which is a concern. Shares have underperformed the industry year to date. Alkermes has a positive record of earnings surprises in recent quarters." (7/19/2019)
  • 2. HC Wainwright analysts commented, "Valuation Our $28 price target for Alkermes is based on our sum-of-the-parts NPV valuation based on each of the company’s marketed products and pipeline assets. Our DCF model utilizes a discount rate of 13.1% based on the company’s WACC (Beta of 1.9, equity risk premium of 6.7%)." (5/31/2019)

Has Alkermes been receiving favorable news coverage?

News stories about ALKS stock have been trending positive this week, InfoTrie reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Alkermes earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Alkermes.

Are investors shorting Alkermes?

Alkermes saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 6,640,000 shares, an increase of 16.1% from the September 30th total of 5,720,000 shares. Based on an average trading volume of 1,210,000 shares, the short-interest ratio is presently 5.5 days. Currently, 4.3% of the shares of the stock are short sold. View Alkermes' Current Options Chain.

Who are some of Alkermes' key competitors?

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Celgene (CELG), Netflix (NFLX), AbbVie (ABBV), NVIDIA (NVDA), Alibaba Group (BABA), Starbucks (SBUX), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC) and Cisco Systems (CSCO).

Who are Alkermes' key executives?

Alkermes' management team includes the folowing people:
  • Mr. Richard F. Pops, Chairman & CEO (Age 57)
  • Dr. Floyd E. Bloom, Co-Founder & Director (Age 82)
  • Mr. James M. Frates, Sr. VP & CFO (Age 52)
  • Mr. David Joseph Gaffin, Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 47)
  • Dr. Craig C. Hopkinson, Sr. VP of Medicines Devel. & Medical Affairs and Chief Medical Officer (Age 51)

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (1.66%), California Public Employees Retirement System (0.22%), Alps Advisors Inc. (0.20%), Russell Investments Group Ltd. (0.14%), Rhenman & Partners Asset Management AB (0.14%) and State of New Jersey Common Pension Fund D (0.09%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Floyd E Bloom, Iain Michael Brown, James M Frates, Laurie Keating, Mark Stejbach, Michael J Landine, Nancy Wysenski, Paul J Mitchell, Richard F Pops and Shane Cooke. View Institutional Ownership Trends for Alkermes.

Which institutional investors are selling Alkermes stock?

ALKS stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, State of New Jersey Common Pension Fund D, Teacher Retirement System of Texas, Alps Advisors Inc., Daiwa Securities Group Inc. and SG Americas Securities LLC. Company insiders that have sold Alkermes company stock in the last year include David Joseph Gaffin, David W Anstice, Michael J Landine, Paul J Mitchell and Richard F Pops. View Insider Buying and Selling for Alkermes.

Which institutional investors are buying Alkermes stock?

ALKS stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Rhenman & Partners Asset Management AB, Russell Investments Group Ltd., Moloney Securities Asset Management LLC, Fox Run Management L.L.C., Steward Partners Investment Advisory LLC, Fjarde AP Fonden Fourth Swedish National Pension Fund and Nisa Investment Advisors LLC. View Insider Buying and Selling for Alkermes.

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $20.08.

How big of a company is Alkermes?

Alkermes has a market capitalization of $3.16 billion and generates $1.09 billion in revenue each year. The company earns $-139,310,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Alkermes employs 2,300 workers across the globe.View Additional Information About Alkermes.

What is Alkermes' official website?

The official website for Alkermes is http://www.alkermes.com/.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]


MarketBeat Community Rating for Alkermes (NASDAQ ALKS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  563 (Vote Outperform)
Underperform Votes:  425 (Vote Underperform)
Total Votes:  988
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe ALKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2019 by MarketBeat.com Staff

Featured Article: Bid-Ask Spread

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel